# US 2024/0002939 A1 · Methods of diagnostic of liver fibrosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002939 A1
- Document ID: US20240002939A1
- Status: Published application
- Kind: A1
- Application number: 18/250,990
- Filed: 2021-10-29
- Published: 2024-01-04
- Earliest claimed: 2020-10-30
- Assignees: Genfit
- Applicants: Genfit
- Inventors: SUNEIL HOSMANE; JÉRÉMY MAGNANENSI; YACINE HAJJI
- Web page: https://patentgrep.com/patent/US20240002939A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/6851: Quantitative amplification
- G01N 33/6893: {related to diseases not provided for elsewhere}
- C12Q 2600/178: miRNA, siRNA or ncRNA
- G01N 2800/085: Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to a method for the identification of NAFLD patients likely to develop advanced liver fibrosis within 52 weeks.

## Claims

### Claim at position 1

1-6. (canceled)

### Claim 7

A method for the identification of a subject as having Non-Alcoholic Fatty Liver Disease (NAFLD) with high likelihood of progression to advanced liver fibrosis within the course of 52 weeks, wherein said method comprises the measure of the level of hsa-miR34a, alpha 2 macroglobulin (A2M), YKL40 and glycated hemoglobin (HbA1c) in a blood-derived sample of said subject, the levels measured being used in a logistic function to calculate a score S, wherein the score S is calculated according to the following logistic function:
S
∼
e
Y
1
+
e
Y
wherein:
Y=k+a*A+b*B+c*C+d*D
wherein the method is derived from the bootstrap model, and wherein:
S is the score;
A is the serum level of hsa-miR-34a in Cq;
B is the serum level of alpha 2 macroglobulin in g/L;
C is the serum level of YKL-40 in pg/ml;
D is the level of HbA1c in percent;
K is the constant of the logistic function;
a is a coefficient associated to the serum level of hsa-miR-34a;
b is a coefficient associated to the serum level of alpha 2 macroglobulin;
c is a coefficient associated to the serum level of YKL-40;
d is a coefficient associated to the level of HbA1c;
wherein:
k is a number comprised between 9.51 and 34.37;
a is a number comprised between −1.17 and −0.47;
b is a number comprised between 0.02 and 0.84;
c is a number comprised between 6.10E-06 and 2.09E-05; and
d is a number comprised between 0.07 and 0.89;
wherein the score S higher or equal to a cut off value, which is 0.63, is indicative of a high likelihood of progressing to advanced fibrosis within the course of 52 weeks.

### Claim 8 (depends on 7)

The method according to claim 7, comprising the measure of the level of hsa-miR34a-5p, HbA1c, YKL-40 and A2M.

### Claim 9 (depends on 7)

The method according to claim 7, wherein the subject has NAFLD with fibrosis stage 0, 1 or 2.

### Claim 10 (depends on 7)

The method according to claim 7, further comprising the measure of liver fibrosis of said subject with a physical method.

### Claim 11 (depends on 10)

The method according to claim 10, wherein measure of liver fibrosis with a physical method is carried out by measuring liver stiffness of said subject.

### Claim 12 (depends on 11)

The method according to claim 11, wherein liver stiffness is measured by measuring the difference in velocity of elastic shear wave propagation in the liver.
